Trial Profile
Efficacy of Azacitidine treatment in patients with acute myeloid leukemia, myelodysplastic syndrome after allogenic hematopoietic stem cell transplantation (allo-HSCT)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Oct 2016
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; T cell replacement therapy
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 28 Oct 2016 New trial record